MacroGenics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from MacroGenics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-30.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 65% of Healthcare companies in United States.
Cash Locked Ratio
$11For every $100 of sales, $11 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
Less money tied up than 78% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -0% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-0% / -8%In 3 years sales changed by -0% while total assets changed by -8%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-15.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
+66%Cash, after subtracting all debt, equals 66% of its market value (net cash).
Higher than 82% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
MacroGenics, Inc. made a loss over the last year. MacroGenics, Inc. owes $0.88 for every $1 it owns. MacroGenics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMacroGenics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.39The share price is 5.39 times MacroGenics, Inc.'s book value per share, higher than 74% of Healthcare companies in United States.
Market cap
$231 MThe total market value of all of MacroGenics, Inc.'s shares at today's price (share price × number of shares), smaller than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$43 MWhat MacroGenics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.67Net worth divided by the number of shares. The share price of $3.63 is 5.4 times this, which is the P/B above.
Return on equity (ROE)
-225.8%MacroGenics, Inc. lost 225.8% of its shareholders' money over the last year, lower than 86% of Healthcare companies in United States.
Owes vs Owns
0.88×MacroGenics, Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Dividend yield
NoneMacroGenics, Inc. does not currently pay a dividend.
Revenue growth
-0%Revenue fell 0% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Profit growth
LossMacroGenics, Inc. made a loss in each of the last two years.
Profit margin
-49.9%MacroGenics, Inc. lost $50 for every $100 of revenue.
Interest cover
Not coveredMacroGenics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashMacroGenics, Inc. held $153 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For MacroGenics, Inc.: $231 M ÷ $43 M (30 Jun 2026) = 5.4.
What is MacroGenics, Inc.'s return on equity?
MacroGenics, Inc. lost 225.8% of its shareholders' money over the last year, lower than 86% of Healthcare companies in United States.
How much does MacroGenics, Inc. owe compared with what it owns?
MacroGenics, Inc. owes $0.88 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Does MacroGenics, Inc. pay a dividend?
No. MacroGenics, Inc. does not currently pay a dividend.
Is MacroGenics, Inc.'s revenue growing?
Revenue fell 0% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.